Arcus Biosciences Inc. (RCUS)
| Bid | 8.62 |
| Market Cap | 914.85M |
| Revenue (ttm) | 258M |
| Net Income (ttm) | -283M |
| EPS (ttm) | -3.14 |
| PE Ratio (ttm) | -2.75 |
| Forward PE | -2.09 |
| Analyst | Buy |
| Ask | 8.66 |
| Volume | 632,784 |
| Avg. Volume (20D) | 1,241,921 |
| Open | 8.72 |
| Previous Close | 8.75 |
| Day's Range | 8.46 - 8.76 |
| 52-Week Range | 6.50 - 18.98 |
| Beta | 1.54 |
About RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Pha...
Analyst Forecast
According to 9 analyst ratings, the average rating for RCUS stock is "Buy." The 12-month stock price forecast is $27, which is an increase of 212.50% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · businesswire.com
Arcus Biosciences to Participate in Two Upcoming Investor ConferencesHAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient...
2 months ago · businesswire.com
Arcus Biosciences, Inc. Announces Underwritten Offering of Common StockHAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...
